葛蘭素史克(ke)(GSK)公布(bu)2022年第三(san)季度業績。季度銷(xiao)(xiao)售(shou)額(e)為78.29億英(ying)鎊(bang)，同(tong)(tong)比(bi)(bi)增(zeng)長(chang)(chang)18%。調整后營業利潤為26.05億英(ying)鎊(bang)，同(tong)(tong)比(bi)(bi)增(zeng)長(chang)(chang)18%。按業務劃分，專用藥(yao)品(pin)業務銷(xiao)(xiao)售(shou)額(e)為27億英(ying)鎊(bang)，同(tong)(tong)比(bi)(bi)增(zeng)長(chang)(chang)36%，其中新冠藥(yao)物(wu)Xevudy銷(xiao)(xiao)售(shou)額(e)為4億英(ying)鎊(bang)。疫苗業務銷(xiao)(xiao)售(shou)額(e)為25億英(ying)鎊(bang)，同(tong)(tong)比(bi)(bi)增(zeng)長(chang)(chang)14%，其中，重(zhong)組帶狀皰疹疫苗Shingrix銷(xiao)(xiao)售(shou)額(e)達到7.6億英(ying)鎊(bang)，同(tong)(tong)比(bi)(bi)增(zeng)長(chang)(chang)51%。一般(ban)藥(yao)品(pin)業務銷(xiao)(xiao)售(shou)額(e)為26億英(ying)鎊(bang)，同(tong)(tong)比(bi)(bi)增(zeng)長(chang)(chang)7%。(全球企業動態)